Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Suppl...( Eligen(R) B12 oral formulation de...),Health

Eligen(R) B12 oral formulation demonstrates 240% improvement in bioavailability versus standard oral Vitamin B12 tablet and different absorption characteristics

Eligen(R) B12 absorption time was 30 minutes

- Public Conference Call to discuss results and future direction set for July 29 -

CEDAR KNOLLS, N.J., July 28 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced new human clinical data demonstrating a new, more bioavailable oral form Vitamin B12 and a potential new avenue for addressing the problems with B12 supplementation. As demonstrated by the data, the Eligen(R) B12 formulation avoids the normal specialized absorption process that limits absorption of Vitamin B12 from current formulations.

"By circumventing the current absorption process, Eligen(R) B12 may present an opportunity to reduce the potential uncertainty associated with oral megadoses of Vitamin B12 and may prevent dependence on the substantial number of injections being taken by millions of individuals," said Michael V. Novinski, President and Chief Executive Officer of Emisphere.

Emisphere's pharmacokinetic study was conducted with 20 healthy male subjects divided into four groups - four subjects received 5mg B12 intravenously, four subjects received 10mg Eligen(R) B12, six subjects received 5mg Eligen(R) B12 and six subjects received a commercially available 5mg B12 tablet. "The 10mg Eligen(R) group served essentially as a pilot group to determine appropriate measurements and assess our protocol," said Gary Riley, DVM, Ph.D., Vice President of Nonclinical Development and Applied Biology at Emisphere. "Following these results, we reduced the amount administered by 50% to a level that is being used in
'/>"/>